News
GSK’s first-quarter Vaccine sales declined 6% due to lower sales of its RSV vaccine, Arexvy, and shingles vaccine, Shingrix.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback